Announcement

Collapse
No announcement yet.

LIVER DISEASE - NON HEPATITIS

Collapse
X
  • Filter
  • Time
  • Show
Clear All
new posts

  • LIVER DISEASE - NON HEPATITIS

    Effect of (-)-Delta(9)-tetrahydrocannabinoid on the hepatic redox state of mice. (full – 2010) http/www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010007500015&lng=en&nrm=iso&tlng=en
    Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation. (full – 2010) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC2829220/?toolubmed
    Recent advances in the understanding of the role of the endocannabinoid system in liver diseases. (full - 2010) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3033442/
    Role of the endocannabinoid system in alcoholic liver disease. (abst – 2010) http/www.ncbi.nlm.nih.gov/pubmed/21525760
    Endogenous cannabinoids in liver disease: Many darts for a single target (abst – 2010) http/www.ncbi.nlm.nih.gov/pubmed/19758727
    Endocannabinoids in liver disease. (full – 2011) http/onlinelibrary.wiley.com/doi/10.1002/hep.24077/full
    Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver (full – 2011) http/www.pnas.org/content/108/15/6323.full
    Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis. (full – 2011) http/www.nature.com/cddis/journal/v2/n6/pdf/cddis201152a.pdf
    Cannabidiol, a Major Phytocannabinoid, as a Potent Atypical Inhibitor for Cytochrome P450 2D6. (full – 2011) http/dmd.aspetjournals.org/content/early/2011/08/05/dmd.111.041384.long
    Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3081988/pdf/nihms278422.pdf
    Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/
    Central Endocannabinoid Signaling Regulates Hepatic Glucose Production and Systemic Lipolysis (full – 2011) http/diabetes.diabetesjournals.org/content/60/4/1055.full
    Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. (full – 2011) http/onlinelibrary.wiley.com/doi/10.1002/hep.23779/full
    Hepatic n-3 Polyunsaturated Fatty Acid Depletion Promotes Steatosis and Insulin Resistance in Mice: Genomic Analysis of Cellular Targets (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3154437/
    Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice. (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3057300/
    Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats. (abst – 2011) http/www.ncbi.nlm.nih.gov/pubmed/21930120
    Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. (abst – 2011) http/www.unboundmedicine.com/medline/ebm/record/21704641/abstract/Identification_of_cytochrome_P450_enzymes_responsi ble_for_metabolism_of_cannabidiol_by_human_liver_m icrosomes_
    Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and cell death (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3081988/
    Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating kupffer cell polarization in mice. (full – 2011) http/onlinelibrary.wiley.com/doi/10.1002/hep.24524/full
    A new cannabinoid 2 receptor agonist HU-910 attenuates oxidative stress, inflammation, and cell death associated with hepatic ischemia/reperfusion injury. (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3423243/
    The novel endocannabinoid virodhamine selectively induces cell death in hepatic stellate cells but not in hepatocytes (abst – 2011) https/www.thieme-connect.com/ejournals/abstract/10.1055/s-0030-1269511
    Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats. (abst – 2011) http/www.ncbi.nlm.nih.gov/pubmed/21930120
    Cannabis Compound Induces Death Of Cells Associated With Liver Fibrosis (news – 2011) http/www.norml.org/index.cfm?Group_ID=8615
    Marijuana Compound Improves Brain And Liver Function In Animal Model Of Hepatic Encephalopathy (news – 2011) http/www.norml.org/index.cfm?Group_ID=8464
    Scripps Research Scientists Discover Inflammation Is Controlled Differently in Brain and Other Tissues (news – 2011) http/www.alphagalileo.org/ViewItem.aspx?ItemId=113766&CultureCode=en
    Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic Fatty liver disease. (full – 2012) http/www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0042259
    Prevention of Fibrosis Progression in CCl4-Treated Rats: Role of the Hepatic Endocannabinoid and Apelin Systems (full – 2012) http/jpet.aspetjournals.org/content/340/3/629.full
    Δ( -Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB(2) receptors. (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3423240/
    Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats. (full – 2012) http/onlinelibrary.wiley.com/doi/10.1002/hep.25625/full
    Characterization of In Vitro Metabolites of CP 47,497, a Synthetic Cannabinoid, in Human Liver Microsomes by LC-MS/MS. (abst – 2012) http/www.ncbi.nlm.nih.gov/pubmed/22931239
    The endocannabinoid 2-arachidonoylglicerol decreases calcium induced cytochrome c release from liver mitochondria. (abst – 2012) http/www.springerlink.com/content/54jm40088728t0pn/
    Serum Metabolic Profiling Study of Hepatocellular Carcinoma Infected with Hepatitis B or Hepatitis C Virus by Using Liquid Chromatography-Mass Spectrometry. (abst – 2012) http/www.ncbi.nlm.nih.gov/pubmed/22946841
    Influence of G1359A polimorphysm of the cannabinoid receptor gene (CNR1) on insulin resistance and adipokines in patients with non alcoholic fatty liver disease. (full – 2013) http/scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-16112012000500039&lng=en&nrm=iso&tlng=en
    Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver (full– 2013) http/onlinelibrary.wiley.com/doi/10.1002/hep.26598/full
    Hepatic Cannabinoid Receptor Type 1 Mediates Alcohol-Induced Regulation of Bile Acid Enzyme Genes Expression Via CREBH (full – 2013) http/www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0068845
    The serine hydrolase ABHD6 Is a critical regulator of the metabolic syndrome. (full – 2013) http/www.cell.com/cell-reports/fulltext/S2211-1247%2813%2900507-X
    Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase. (full – 2013) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3839776/
    US Patent Application 20130171145 - METHODS OF TREATING LIVER DISEASE (full – 2013) http/www.freepatentsonline.com/y2013/0171145.html
    Cannabidiol is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19. (full – 2013) https/www.jstage.jst.go.jp/article/dmpk/28/4/28_DMPK-12-RG-129/_pdf
    Cannabinoid signaling and liver therapeutics. (full – 2013) http/www.journal-of-hepatology.eu/article/S0168-8278%2813%2900212-2/fulltext
    The role of endocannabinoids system in fatty liver disease and therapeutic potentials. (full – 2013) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3745655/
    Effects of anandamide on proliferation of and pErk expression in primary hepatic stellate cells of schistosome-induced liver fibrosis mice (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/23663762
    Fatty acid amide hydrolase but not monoacyl glycerol lipase controls cell death induced by the endocannabinoid 2-arachidonoyl glycerol in hepatic cell populations. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/23806692
    Functional relevance of the cannabinoid receptor 2 - heme oxygenase pathway: A novel target for the attenuation of portal hypertension. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/24007798
    Protective effect of cannabidiol against cadmium hepatotoxicity in rats. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/23993482
    The novel endocannabinoid noladin ether holds putative anti-fibrotic properties by selectively inducing cell death in hepatic stellate cells (abst – 2013) https/www.thieme-connect.com/ejournals/abstract/10.1055/s-0032-1331948
    Science/Animal: CBD inhibits the activity of a certain liver enzyme (news – 2013) http/www.cannabismed.org/english/bulletin/ww_en_db_cannabis_artikel.php?id=391&search_pattern=2013#10
    Smoking cannabis does not accelerate progression of liver disease in people with HIV/HCV co-infection (news – 2013) http/www.aidsmap.com/Smoking-cannabis-does-not-accelerate-progression-of-liver-disease-in-peoplewith-HIVHCV-co-infection/page/2707524/
    A new face of endocannabinoids in pharmacotherapy. Part II. Role of endocannabinoids in inflammation-derived cardiovascular diseases. (full – 2014) http/www.jpp.krakow.pl/journal/archive/04_14/pdf/183_04_14_article.pdf
    Endocannabinoid Receptors Gene Expression in Morbidly Obese Women with Nonalcoholic Fatty Liver Disease (full – 2014) http/www.hindawi.com/journals/bmri/2014/502542/
    Vascular targets for cannabinoids: animal and human studies. (full – 2014) http/onlinelibrary.wiley.com/doi/10.1111/bph.12560/full
    The peripheral cannabinoid receptor 1 antagonist VD60 efficiently inhibits carbon tetrachloride-intoxicated hepatic fibrosis progression. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24459189
    CB1 blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/22828945
    Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24398069
    Review article: the endocannabinoid system in liver disease, a potential therapeutic target. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24612021
    Upregulation of Cannabinoid Receptor-1 and Fibrotic Activation of Mouse Hepatic Stellate Cells during Schistosoma J. Infection: Role of NADPH Oxidase. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24657416
    Therapeutical Potential of CB2 Receptors in Immune-Related Diseases. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24720538
    Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy (abst – 2014) http/www.sciencedirect.com/science/article/pii/S0891584913015670
    Potential therapeutic applications of cannabinoids in gastrointestinal and liver diseases: Focus on Δ9-tetrahydrocannabinol pharmacology (abst – 2014) http/onlinelibrary.wiley.com/doi/10.1002/9781118451281.ch7/summary
    (Mo1121) Cannabinoid Use Decreases ED Utilization in a Gastroenterology Clinic Population (abst – 2014) http/www.gastrojournal.org/article/S0016-5085%2814%2962037-0/pdf
    New Study: Cannabis May Protect Liver From Alcohol Related Damage (news – 2014) http/cannabisni.com/medicinal-cannabis-news/2848-new-study-cannabis-may-protect-liver-from-alcoholrelated-damage
    Bisdemethoxycurcumin Induces Apoptosis in Activated Hepatic Stellate Cells via Cannabinoid Receptor 2 (link to PDF – 2015) http://www.mdpi.com/1420-3049/20/1/1277
    Two non-psychoactive cannabinoids reduce intra-cellular lipid levels and inhibit hepatosteatosis (abst – 2015) http://www.ncbi.nlm.nih.gov/pubmed/25595882
Working...
X
Powered by vBulletin Copyright © 2015 vBulletin Solutions, Inc.